Nov 12, 2026
How Could Eledon Pharmaceuticals (NASDAQ:ELDN) Fare When It Reports Results on November 13, 2026, With a -0.19 EPS Estimate?
Eledon Pharmaceuticals (NASDAQ:ELDN) is expected to report a loss of $0.19 per share for the third quarter of 2026 when it releases results after market close on November 13, 2026. This projection follows a Q2 2026 net loss of $31.6 million ($0.27 per share). The clinical-stage company, valued at $216.97 million, had $88.8 million in cash and equivalents as of June 30, 2026, sufficient to fund operations into Q2 2027, and investors will be watching for updates on its Phase 3 kidney transplant study and financing plans.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish
Oct 30, 2026
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
Eledon Pharmaceuticals announced positive patient-reported outcomes from its Phase 2 BESTOW trial, showing tegoprubart significantly improved health-related quality of life and reduced symptom burden compared to tacrolimus in kidney transplant patients. These sustained improvements through 12 months post-transplantation were presented at ASN Kidney Week 2026, further validating tegoprubart's potential as a transformative treatment option. The data indicates that tegoprubart offers meaningful quality of life advantages alongside strong clinical outcomes.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish